Amphastar Highlights Branded Drug Growth and Pipeline Priorities

Pharmaceutical company outlines performance, milestones, and competitive dynamics for key products like Baqsimi and Primatene Mist.

Apr. 15, 2026 at 12:03am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a glass vial, a syringe, and a nasal spray device, symbolizing Amphastar's expertise in injectable and nasal delivery products.Amphastar's diverse portfolio of injectable and inhalation products reflects the company's focus on complex pharmaceutical development and manufacturing.Rancho Cucamonga Today

Amphastar Pharmaceuticals executives discussed the company's 2025 performance, 2026 outlook, and pipeline priorities during a fireside chat at the Needham Healthcare Conference. Key topics included continued growth of branded drugs Baqsimi and Primatene Mist, competitive pressures in the injectable generics market, and the timing of new product launches.

Why it matters

As a diversified pharmaceutical company focused on complex generics and branded drugs, Amphastar's performance and pipeline provide insights into industry dynamics, particularly around the challenges and opportunities in the injectable and respiratory drug markets.

The details

Amphastar executives highlighted several growth drivers in 2025, including strong demand for the nasal glucagon product Baqsimi and solid sales of the over-the-counter asthma inhaler Primatene Mist. However, the company also faced competitive pressures in its injectable generics portfolio, especially for glucagon and epinephrine products. Looking ahead, Amphastar plans to launch several new products in 2026, including an intranasal epinephrine and an insulin biosimilar, while continuing to evaluate business development opportunities to expand its branded and complex generic offerings.

  • Amphastar expects to hit $175 million in Baqsimi sales this year, triggering a $100 million milestone payment in August.
  • The company plans to launch the product AMP-007 in the early second quarter of 2026.
  • Amphastar's insulin biosimilar AMP-004 and diabetes product AMP-018 are both expected to launch in 2027.

The players

Bill Peters

Chief Financial Officer of Amphastar Pharmaceuticals.

Dan Dischner

Senior Vice President of Corporate Communications at Amphastar Pharmaceuticals.

Tony Marrs

Executive Vice President of Clinical and Regulatory Affairs at Amphastar Pharmaceuticals.

Serge Belanger

Senior Analyst at Needham & Company.

Amphastar Pharmaceuticals

A specialty pharmaceutical company focused on the development, manufacturing, and commercialization of injectable and inhalation products.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.